Drug Trial Radar · NCT06525298
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Sep 9, 2024
Primary completion
Sep 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Eisbach Bio GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- M.D. Anderson Cancer Center
- First posted
- Jul 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).
Conditions
- Advanced Solid Tumor
- Homologous Recombination Deficiency
- HRR Deficiency
Interventions
EIS-12656Drug
EIS-12656 tablets given daily
PARPiDrug
as per USPI/SmPC
Trastuzumab deruxtecanDrug
as per USPI/SmPC
Darolutamide (BAY 1841788)Drug
as per USPI/SmPC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and percentage of participants experiencing treatment-emergent adverse events (TEAEs)Time frame: From screening until end of treatment follow-up (45 days after last dose) (up to 7 months)
- Number and percentage of participants experiencing a dose limiting toxicity (DLT) (dose escalation part only)Time frame: Within 21 days of first dose
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
LSU Health Sciences Center- Shreveport
Shreveport, Louisiana · Recruiting
Duke Cancer Institute
Durham, North Carolina · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.